A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment

This is a non-randomized, open label, multi-site, Phase 1 First in Human (FIH) study split into two parts. The first part (Part A) is a dose escalation and the second part (Part B) will be to confirm the dose. The aim of the study is to collect data to assess whether the study product, INT2104, is safe and tolerable, to understand how well INT2104 works in the human body and to select the dose to take into a Phase 2 study. All participants will receive one intravenous (IV) infusion of INT2104. Each participant in the study will follow the same study treatment schedule and will proceed through the following study periods: * Screening Period: participant will be assessed for eligibility * Study Day 1: participants who meet all eligibility criteria will receive INT2104 by a one-time infusion * Post-treatment Assessment Period: participants will be followed regularly with clinic visits after they receive INT2104